Literature DB >> 21989602

Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).

Y-T Xiang1, C-Y Wang, T-M Si, E H M Lee, Y-L He, G S Ungvari, H F K Chiu, S-Y Yang, M-Y Chong, C-H Tan, E-H Kua, S Fujii, K Sim, K H Yong, J K Trivedi, E-K Chung, P Udomratn, K-Y Chee, N Sartorius, N Shinfuku.   

Abstract

OBJECTIVE: This study aimed to identify trends in the use of antipsychotic polypharmacy (APP) and their demographic and clinical correlates in the treatment of schizophrenia in Asia between 2001 and 2009.
METHOD: A total of 6,761 schizophrenia inpatients in 9 Asian countries and territories were examined; 2,399 in 2001, 2,136 in 2004, and 2,226 in 2009. Patients’ socio-demographic and clinical characteristics and prescriptions of psychotropic drugs were recorded using a standardized protocol and data collection procedure.
RESULTS: The proportion of APP prescription decreased from 46.8 % in 2001, to 38.3 % in 2004, and increased to 43.4 % in 2009, with wide intercountry variations at each survey. Multiple logistic regression analysis of the whole sample revealed that patients on APP were younger, had a higher dose of antipsychotics in chlorpromazine equivalents, and more severe positive and negative symptoms. They were also more likely to receive depot and fi rst-generation antipsychotic drugs.
CONCLUSIONS: The frequency of APP prescription varied between countries and territories, suggesting that a host of clinical and socio-cultural factors played a role in determining APP use in Asia. To resolve the discrepancy between treatment recommendation and clinical practice, regular reviews of prescription patterns are needed. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989602     DOI: 10.1055/s-0031-1286345

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  15 in total

1.  Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Authors:  Y-T Xiang; G S Ungvari; C U Correll; H F K Chiu; N Shinfuku
Journal:  Epidemiol Psychiatr Sci       Date:  2015-08-20       Impact factor: 6.892

2.  Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot.

Authors:  Leslie Citrome; Zhenchao Guo; Iftekhar Kalsekar; Robert A Forbes; Tony Hebden
Journal:  Innov Clin Neurosci       Date:  2012-03

3.  Cardiac Sudden Death in Psychiatric Patients.

Authors:  Hiroyuki Uchida; Takefumi Suzuki
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

Review 4.  A bibliometric study of scientific research conducted on second-generation antipsychotic drugs in Singapore.

Authors:  Francisco López-Muñoz; Kang Sim; Winston Wu Shen; Lorena Huelves; Raquel Moreno; Juan de Dios Molina; Gabriel Rubio; Concha Noriega; Miguel Ángel Pérez-Nieto; Cecilio Alamo
Journal:  Singapore Med J       Date:  2014-01       Impact factor: 1.858

5.  Analysis of the trends of polypharmacy and high-dose prescriptions in Japan.

Authors:  Naotaka Shinfuku
Journal:  Asia Pac Psychiatry       Date:  2021-09-14       Impact factor: 3.788

6.  Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.

Authors:  FangFang Sun; Eileen M Stock; Laurel A Copeland; John E Zeber; Brian K Ahmedani; Sandra B Morissette
Journal:  Am J Health Syst Pharm       Date:  2014-05-01       Impact factor: 2.637

7.  Reducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study.

Authors:  Peter Hjorth; Reinhold Kilian; Helle Østermark Sørensen; Susan Engelbrechsen Eriksen; Annette Sofie Davidsen; Signe Olrik Wallenstein Jensen; Povl Munk-Jørgensen
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

8.  Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.

Authors:  Yoshio Yamanouchi; Tsuruhei Sukegawa; Ataru Inagaki; Toshiya Inada; Takashi Yoshio; Reiji Yoshimura; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-11       Impact factor: 5.176

9.  Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy.

Authors:  Hee-Yun Kim; Hee-Won Lee; Seung-Ho Jung; Min-Hee Kang; Jae-Nam Bae; Jeong-Seop Lee; Chul-Eung Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-08-12       Impact factor: 2.582

10.  Psychopharmacological treatment for schizophrenia: less is more.

Authors:  Chuanyue Wang
Journal:  Shanghai Arch Psychiatry       Date:  2015-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.